These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

684 related articles for article (PubMed ID: 1720630)

  • 21. Strain specificity and binding affinity requirements of neutralizing monoclonal antibodies to the C4 domain of gp120 from human immunodeficiency virus type 1.
    Nakamura GR; Byrn R; Wilkes DM; Fox JA; Hobbs MR; Hastings R; Wessling HC; Norcross MA; Fendly BM; Berman PW
    J Virol; 1993 Oct; 67(10):6179-91. PubMed ID: 7690420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.
    Berman PW; Matthews TJ; Riddle L; Champe M; Hobbs MR; Nakamura GR; Mercer J; Eastman DJ; Lucas C; Langlois AJ
    J Virol; 1992 Jul; 66(7):4464-9. PubMed ID: 1602554
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans.
    Moore JP; Ho DD
    J Virol; 1993 Feb; 67(2):863-75. PubMed ID: 7678308
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serologic evaluation of human immunodeficiency virus type 1-infected individuals from Argentina and the United States indicates a similar distribution of subgroup B isolates.
    Warren RQ; Wong MT; Melcher GP; Blatt SP; Cahn P; Perez H; Zapiola I; Bouzas MB; Muchinik G; Anderson SA
    J Clin Microbiol; 1995 Feb; 33(2):481-3. PubMed ID: 7714212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human immunodeficiency virus (HIV) type 1 strain MN neutralizing antibody in HIV-infected children: correlation with clinical status and prognostic value.
    Robert-Guroff M; Roilides E; Muldoon R; Venzon D; Husson R; Marshall D; Gallo RC; Pizzo PA
    J Infect Dis; 1993 Mar; 167(3):538-46. PubMed ID: 7680059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cross-neutralizing antibodies to HIV-1ANT70 and HIV-1IIIB in sera of African and Belgian HIV-1-infected individuals.
    Nkengasong JN; Peeters M; Ndumbe P; Janssens W; Willems B; Fransen K; Ngolle M; Piot P; van der Groen G
    AIDS; 1994 Aug; 8(8):1089-96. PubMed ID: 7986404
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Greater diversity of the HIV-1 V3 neutralization domain in Tanzania compared with The Netherlands: serological and genetic analysis.
    Zwart G; Wolfs TF; Bookelman R; Hartman S; Bakker M; Boucher CA; Kuiken C; Goudsmit J
    AIDS; 1993 Apr; 7(4):467-74. PubMed ID: 8507412
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Maternofetal transmission of human immunodeficiency virus-1: the role of antibodies to the V3 primary neutralizing domain.
    Rubinstein A; Goldstein H; Calvelli T; Devash Y; Rubinstein R; Soeiro R; Lyman W
    Pediatr Res; 1993 Jan; 33(1 Suppl):S76-8; discussion S78-9. PubMed ID: 8433879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Envelope sequence variability and serologic characterization of HIV type 1 group O isolates from equatorial guinea.
    Hunt JC; Golden AM; Lund JK; Gürtler LG; Zekeng L; Obiang J; Kaptué L; Hampl H; Vallari A; Devare SG
    AIDS Res Hum Retroviruses; 1997 Aug; 13(12):995-1005. PubMed ID: 9264286
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
    Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
    Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cellular and antibody responses directed against the HIV-1 principal neutralizing domain in HIV-1-infected children.
    Wiseman G; Rubinstein A; Martinez P; Lambert S; Devash Y; Goldstein H
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):839-45. PubMed ID: 1742076
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Broadly neutralizing, MN-like PND-directed antibodies in Rwandan children with long-term HIV1 infection.
    Fraisier C; Van de Perre P; Lepage P; Hitimana DG; Karita E; Desgranges C
    Res Virol; 1995; 146(3):201-10. PubMed ID: 7481092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunodominance and antigenic variation of the principal neutralization domain of HIV-1.
    Zwart G; Langedijk H; van der Hoek L; de Jong JJ; Wolfs TF; Ramautarsing C; Bakker M; de Ronde A; Goudsmit J
    Virology; 1991 Apr; 181(2):481-9. PubMed ID: 2014634
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variant-specific monoclonal and group-specific polyclonal human immunodeficiency virus type 1 neutralizing antibodies raised with synthetic peptides from the gp120 third variable domain.
    Laman JD; Schellekens MM; Abacioglu YH; Lewis GK; Tersmette M; Fouchier RA; Langedijk JP; Claassen E; Boersma WJ
    J Virol; 1992 Mar; 66(3):1823-31. PubMed ID: 1637373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Presentation of native epitopes in the V1/V2 and V3 regions of human immunodeficiency virus type 1 gp120 by fusion glycoproteins containing isolated gp120 domains.
    Kayman SC; Wu Z; Revesz K; Chen H; Kopelman R; Pinter A
    J Virol; 1994 Jan; 68(1):400-10. PubMed ID: 7504740
    [TBL] [Abstract][Full Text] [Related]  

  • 38. V3-specific polyclonal antibodies affinity purified from sera of infected humans effectively neutralize primary isolates of human immunodeficiency virus type 1.
    Krachmarov CP; Kayman SC; Honnen WJ; Trochev O; Pinter A
    AIDS Res Hum Retroviruses; 2001 Dec; 17(18):1737-48. PubMed ID: 11788025
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.